Blue Note Therapeutics Announces New Collaboration for its Prescription Digital Therapeutic Candidate
Blue Note Therapeutics enters a new collaboration under Memorial Sloan Kettering Cancer Center's Innovation Hub to help advance the company's PDT and increase capacity to reach patients.
Blue Note Therapeutics Raises $5.2M in Additional Series A Funding
Company raises additional Series A financing strengthening capacity to develop evidence-based therapeutics that serve an increasing number of cancer patients.
Durham VA Health Care System and Blue Note Therapeutics Commence Phase 2 Study of First-of-its-Kind Prescription Digital Therapeutic to Address Cancer-Related Distress in Veterans
Blue Note has partnered with Durham VA Health Care System to address cancer-related distress in veterans where there is an immediate opportunity to improve and expand access to quality mental health care.
Cancer-related distress, which can be defined as any unpleasant feeling, emotion, or experience that affects a cancer patient’s quality of life or ability to cope with cancer diagnosis and treatment, affects millions of people. Fewer than half of those who experience cancer-related distress have access to the mental health care they need to find relief. Blue Note Therapeutics is working to close this gap.Learn more